Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

The Obesity Drugs Market is experiencing unprecedented growth, driven by increasing global obesity rates, sedentary ...

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Altimmune, Inc. (NASDAQ:ALT) was one of ...

Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled ...

Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $22.17, implying a 284.90% upside from current levels. In a report released yesterday, Piper Sandler also ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the ...

Altimmune Inc. (ALT) reported its first-quarter 2025 financial results, revealing a narrower-than-expected loss. The company’s reported earnings per share (EPS) were -$0.26, surpassing analyst ...

GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

Shares of Altimmune, Inc. (ALT) have gained 39.4% over the past four weeks to close the last trading session at $5.80, but there could still be a solid upside left in the stock if short-term price ...

Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of ...

Altimmune, Inc., a late clinical-stage biopharmaceutical company, announced that it will release its first quarter 2025 financial results on May 13, 2025. A conference call to discuss these ...